+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors



Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors



Gene Therapy 10(23): 1982-1991



Conditionally replicative adenoviruses (CRAds) are potentially useful agents for anticancer virotherapy approaches. However, lack of coxsackievirus and adenovirus receptor (CAR) expression on many primary tumor cells limits the oncolytic potency of CRAds. This makes the concept of targeting, that is, redirecting infection via CAR-independent entry pathways, relevant for CRAd development. Bispecific adapter molecules constitute highly versatile means for adenovirus targeting. Here, we constructed a CRAd with the DELTA24 E1A mutation that produces a bispecific single-chain antibody directed towards the adenovirus fiber knob and the epidermal growth factor receptor (EGFR). This EGFR-targeted CRAd exhibited increased infection efficiency and oncolytic replication on CAR-deficient cancer cells and augmented lateral spread in CAR-deficient 3-D tumor spheroids in vitro. When compared to its parent control with native tropism, the new CRAd exhibited similar cytotoxicity on CAR-positive cancer cells, but up to 1000-fold enhanced oncolytic potency on CAR-deficient, EGFR-positive cancer cells. In addition, EGFR-targeted CRAd killed primary human CAR-deficient brain tumor specimens that were refractory to the parent control virus. We conclude, therefore, that CRAds expressing bispecific targeting adapter molecules are promising agents for cancer treatment. Their use is likely to result in enhanced oncolytic replication in cancerous tissues and thus in more effective tumor regression.

Accession: 010372111

Download citation: RISBibTeXText

PMID: 14528322

DOI: 10.1038/sj.gt.3302103


Related references

Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Research 62(21): 6165-6171, 2002

Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. Journal of Gene Medicine 7(5): 584-594, 2005

A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clinical Cancer Research 7(1): 120-126, 2001

Enhanced oncolytic potency of replicative adenovirus expressing p53. Drug Resistance Updates 6(1): 5-7, 2003

The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clinical Cancer Research 8(11): 3348-3359, 2002

Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Research 64(16): 5753-5759, 2004

A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5 Delta 24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy. International Journal of Molecular Medicine 18(4): 751-759, 2006

Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Therapy 10(8): 583-588, 2003

Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2. Molecular Cancer Therapeutics 4(6): 1013-1018, 2005

Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model. Urology 70(5): 1009-1013, 2007

A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Research 67(18): 8783-8790, 2007

Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs. Cancer BioTherapy and Radiopharmaceuticals 21(6): 601-606, 2007

Enhanced antitumoral efficacy and immune response following conditionally replicative adenovirus containing constitutive HSF1 delivery to rodent tumors. Journal of Translational Medicine 10: 101, 2012

A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors. Cancer BioTherapy and Radiopharmaceuticals 25(4): 487-495, 2011

The therapeutic gene carboxylesterase-2 enhances the oncolytic potential of the conditionally replicative adenovirus AdDELTA24 in combination with CPT-11. Proceedings of the American Association for Cancer Research Annual Meeting 44: 143, 2003